Optimism Surrounds Praxis Precision Medicines (PRAX) Amid Potential FDA Approval for Ulixacaltamide

As of the adjacent of play connected April 24, the broader statement sentiments towards Praxis Precision Medicines Inc. (NASDAQ:PRAX) remained powerfully bullish. The banal received sum from 16 analysts, 14 of whom assigned Buy ratings and 1 gave a Hold call. With conscionable 1 Sell rating, it carries a median 1-year people terms of $625.31, starring to an upside imaginable of much than 81% for investors. This makes it 1 of the standout names wrong the biotech space.

Copyright: nexusplexus / 123RF Stock Photo

On April 10, Raymond James assigned a Strong Buy standing to Praxis Precision Inc. (NASDAQ:PRAX). The steadfast acceptable a people terms of $815, which leads to a lucrative upside imaginable of much than 136% astatine the existent level.

The steadfast reflected connected the prevailing bearish sentiment towards the stock, which it believes is based connected a predetermined decision wholly devoid of empirical evidence. It emphasized that the expected FDA support of ulixacaltamide during aboriginal 2027 could enactment arsenic a definitive commercialized catalyst for the stock. The steadfast besides believes that astatine the existent valuation level, investors are importantly undervaluing the likelihood of ceremonial regulatory success.

Praxis Precision Medicines Inc. (NASDAQ:PRAX) is progressive successful processing therapies to cure disorders related to the cardinal tense system, which are characterized by neuronal excitation-inhibition imbalance. These disorders see epilepsy, question disorders, and depression. The institution utilizes its proprietary platforms similar Cerebrum and Solidus to people specified imbalances.

While we admit the imaginable of PRAX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years.

Disclosure: None. Follow Insider Monkey connected Google News.